18 studies found for:    Avanir
Hide Display Options

Display Options

Study Details
Participant Details
Rank Status Study
1 Completed PRISM Registry: Pseudobulbar Affect Registry Series
Conditions: Alzheimer's Disease;   Amyotrophic Lateral Sclerosis (ALS);   Multiple Sclerosis (MS);   Parkinson's Disease;   Stroke;   Traumatic Brain Injury
2 Recruiting Efficacy, Safety, and Tolerability Study of AVP-786 as an Adjunctive Therapy in Patients With Major Depressive Disorder With an Inadequate Response to Antidepressant Treatment
Condition: Depressive Disorder, Treatment-Resistant
Interventions: Drug: AVP-786 (d6-dextromethorphan hydrobromide and quinidine sulfate combination);   Drug: Placebo
3 Completed
Has Results
Safety and Efficacy of AVP-923 in PBA Patients With ALS or MS
Condition: Pseudobulbar Affect (PBA)
Interventions: Drug: dextromethorphan hydrobromide 20 mg and quinidine sulfate 10 mg;   Drug: dextromethorphan hydrobromide 30 mg and quinidine sulfate 10 mg;   Drug: Placebo
4 Recruiting Drug Interaction Study Between AVP-923 and Itraconazole and Between AVP-786 and Itraconazole in Healthy Adult Subejcts
Condition: Healthy
Interventions: Drug: AVP-923;   Drug: AVP-786;   Drug: Itraconazole
5 Completed Safety and Efficacy of AVP-923 for Pseudobulbar Affect in Multiple Sclerosis Patients
Condition: Multiple Sclerosis
Intervention: Drug: AVP-923
6 Completed Safety and Efficacy of AVP-923 in the Treatment of Central Neuropathic Pain in Multiple Sclerosis
Conditions: Central Neuropathic Pain;   Multiple Sclerosis
Intervention: Drug: AVP-923
7 Active, not recruiting Safety, Tolerability and Effectiveness of Nuedexta in the Treatment of Pseudobulbar Affect (PBA)
Conditions: Pseudobulbar Affect (PBA);   Stroke;   Dementia;   Traumatic Brain Injury (TBI)
Intervention: Drug: Nuedexta (DM 20 mg/Q 10 mg)
8 Completed Safety and Efficacy of Dextromethorphan and Quinidine in the Treatment of the Pain of Diabetic Neuropathy
Conditions: Pain;   Diabetic Neuropathy
Intervention: Drug: Neurodex
9 Active, not recruiting Safety and Efficacy of AVP-923 in the Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease Patients
Conditions: Dyskinesia;   Parkinson's Disease
Interventions: Drug: AVP-923-45;   Drug: Placebo
10 Completed A Phase 1, Drug Interaction Study Between AVP-786 and Paroxetine and Between AVP-786 and Duloxetine in Healthy Subjects
Condition: Drug-drug Interaction
Interventions: Drug: AVP-786;   Drug: Paroxetine;   Drug: Duloxetine
11 Completed Efficacy, Safety and Tolerability Study of AVP-923 (Dextromethorphan/Quinidine) for Treatment of Symptoms of Agitation in Alzheimer's Patients
Conditions: Agitation;   Alzheimer's Disease
Interventions: Drug: AVP-923 (dextromethorphan/quinidine);   Drug: Placebo
12 Completed Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS
Condition: Amyotrophic Lateral Sclerosis
Intervention: Drug: AVP-923
13 Completed Pharmacokinetics (PK) and Tolerability of AVP-786 in Healthy Volunteers
Condition: Healthy
Interventions: Drug: AVP-786 Dose 1;   Drug: AVP-786 Dose 2;   Drug: AVP-786 Dose 1/Q Dose 1;   Drug: AVP-786 Dose 1/Q Dose 2;   Drug: AVP-786 Dose 2/Q Dose 2;   Drug: AVP-923
14 Active, not recruiting A Phase 1 Study Comparing AVP-786 With AVP-923
Condition: Healthy Subject Pharmacokinetics
Interventions: Drug: AVP-786;   Drug: AVP-923
15 Completed Safety Study of AVP-923 in the Treatment of IEED (Involuntary Emotional Expression Disorder) Also Known as Pseudobulbar Affect (Episodes of Uncontrolled Crying and/or Laughter)
Conditions: Alzheimer's Disease;   Stroke;   Parkinson's Disease;   Traumatic Brain Injury
Intervention: Drug: AVP-923
16 Completed A Phase-1 Study to Assess the Pharmacokinetics, Safety and Tolerability of AVP-786 in Healthy Volunteers
Condition: Healthy
Interventions: Drug: AVP-786;   Drug: AVP-923
17 Recruiting Nuedexta for the Prevention and Modification of Disease Progression in Episodic Migraine
Condition: Episodic Migraine
Intervention: Drug: Dextromethorphan and quinidine
18 Recruiting Nuedexta in the Treatment of Pseudobulbar Affect in Patients With Alzheimer's Disease
Conditions: Alzheimer's Disease;   Pseudobulbar Affect (PBA)
Intervention: Drug: Nuedexta (20/10)

Indicates status has not been verified in more than two years